The weekly litigation news digest is live. Subscribe now

Patent Oppositions in metabolic drugs industry

Explore the competitive field of metabolic drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in metabolic drugs technology and learn how to protect your intellectual property.

Get Patent Opposition Report for metabolic drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Nov 20, 2025
CompanyTotal Oppositions
NOVARTIS182
BOEHRINGER INGELHEIM111
NOVO NORDISK75
AMGEN44
NUTRICIA41
BRISTOL MYERS SQUIBB37
CELGENE37
NESTLE34
PFIZER31
ASTELLAS PHARMA29

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the metabolic drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the metabolic drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Nov 20, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name
Use Of Isoxazoline Compounds For Treating DemodicosisINTERVETOct 28, 2025CEVA SANTE ANIMALE
Use Of Whey Protein Micelles For Controlling Postprandial Glucose ResponseNESTLEOct 15, 2025ARLA FOODS AMBA
Use Of Whey Protein Micelles For Controlling Postprandial Glucose ResponseNESTLEOct 13, 2025FRESENIUS KABI DEUTSCHLAND
Method And Compositions For Cellular ImmunotherapyFRED HUTCHINSON CANCER RESEARCH CENTEROct 8, 2025BOULT WADE TENNANT
Use Of Isoxazoline Compounds For Treating DemodicosisINTERVETOct 3, 2025VIRBAC
Antimicrobial Compounds From The Genus DelftiaMINISTRY OF HEALTHOct 1, 2025SCORPIO
ImmunoconjugatesBOLT BIOTHERAPEUTICSSep 30, 2025STRAWMAN
Combination DrugCHUGAI SEIYAKU KABUSHIKI KAISHASep 24, 2025BOTTI & FERRARI
Perinatal Administration Of Short-Chain Fructooligosaccharides In Order To Prevent Metabolic Disorders Linked To An Unbalanced Diet At Adult AgeINRASep 24, 2025SUDZUCKER
Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIMSep 18, 2025ELEND

To stay ahead in the competitive metabolic drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the metabolic drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Nov 20, 2025
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY22
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Aug 18, 2021Formulations Of EnzalutamideMEDIVATION PROSTATE THERAPEUTICS12
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIM11
Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNA10
Sep 14, 2022Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIM10